We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Arrests by U.S. Immigration and Customs Enforcement are becoming more common, but what happens once people are taken into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback